“Gilead has Sovaldi tied up and since it’s the backbone, we’ve focused on this at the outset. If we can remove patents on Sovaldi, there are generics and other combinations (that might be developed by still other companies) that could potentially become available, hopefully, at more affordable prices.” – Tahir Amin